BRPI0915973A2 - uso de uma beta defensina humana - Google Patents

uso de uma beta defensina humana Download PDF

Info

Publication number
BRPI0915973A2
BRPI0915973A2 BRPI0915973-8A BRPI0915973A BRPI0915973A2 BR PI0915973 A2 BRPI0915973 A2 BR PI0915973A2 BR PI0915973 A BRPI0915973 A BR PI0915973A BR PI0915973 A2 BRPI0915973 A2 BR PI0915973A2
Authority
BR
Brazil
Prior art keywords
hbd2
beta defensin
human
tnf
lps
Prior art date
Application number
BRPI0915973-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Tanja Maria Rosenkilde Kjaer
Thomas Kruse
Per Holse Mygind
Karoline Sidelmann Brinch
Soeren Kjaerulff
Birgitte Andersen
Original Assignee
Novozymes Adenium Biotech As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41530820&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0915973(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novozymes Adenium Biotech As filed Critical Novozymes Adenium Biotech As
Priority to BRPI0924481-6A priority Critical patent/BRPI0924481A2/pt
Publication of BRPI0915973A2 publication Critical patent/BRPI0915973A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0915973-8A 2008-07-18 2009-07-17 uso de uma beta defensina humana BRPI0915973A2 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BRPI0924481-6A BRPI0924481A2 (pt) 2008-07-18 2009-07-17 Uso de uma beta defensina de mamífero, e, método para tratar uma doença intestinal inflamatória

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP08160761 2008-07-18
EP08160761.6 2008-07-18
EP08162486 2008-08-15
EP08162486.8 2008-08-15
EP08163614 2008-09-03
EP08163614.4 2008-09-03
PCT/EP2009/059253 WO2010007166A2 (fr) 2008-07-18 2009-07-17 Traitement de maladies intestinales inflammatoires par des bêta-défensines de mammifères

Publications (1)

Publication Number Publication Date
BRPI0915973A2 true BRPI0915973A2 (pt) 2013-05-07

Family

ID=41530820

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0915973-8A BRPI0915973A2 (pt) 2008-07-18 2009-07-17 uso de uma beta defensina humana
BRPI0924481-6A BRPI0924481A2 (pt) 2008-07-18 2009-07-17 Uso de uma beta defensina de mamífero, e, método para tratar uma doença intestinal inflamatória

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0924481-6A BRPI0924481A2 (pt) 2008-07-18 2009-07-17 Uso de uma beta defensina de mamífero, e, método para tratar uma doença intestinal inflamatória

Country Status (20)

Country Link
US (4) US8232242B2 (fr)
EP (2) EP2399600A1 (fr)
JP (2) JP2011528333A (fr)
KR (1) KR20110092325A (fr)
CN (2) CN102159233A (fr)
AP (2) AP2011005755A0 (fr)
AR (2) AR072032A1 (fr)
AU (1) AU2009272681A1 (fr)
BR (2) BRPI0915973A2 (fr)
CA (2) CA2730789A1 (fr)
CL (1) CL2011000099A1 (fr)
EA (2) EA201170219A1 (fr)
IL (2) IL210715A0 (fr)
MX (1) MX2011000568A (fr)
NZ (2) NZ590468A (fr)
PH (1) PH12012501542A1 (fr)
SG (1) SG172709A1 (fr)
TW (2) TW201004640A (fr)
WO (1) WO2010007166A2 (fr)
ZA (1) ZA201100461B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2320929B1 (fr) * 2008-07-18 2019-05-29 Defensin Therapeutics ApS Bêta-défensines humaines pour son utilisation dans le traitement des maladies inflammatoires
EP2320928B1 (fr) * 2008-07-18 2012-11-07 Novozymes Adenium Biotech A/S Traitement de la polyarthrite rhumatoïde avec des bêta défensines humaines
BRPI0915973A2 (pt) 2008-07-18 2013-05-07 Novozymes Adenium Biotech As uso de uma beta defensina humana
KR101257228B1 (ko) * 2010-06-16 2013-04-29 주식회사 나이벡 항균 또는 항염증 활성을 가지는 펩타이드 및 이를 유효성분으로 함유하는 약제학적 조성물
CA2832859C (fr) 2011-04-15 2020-06-16 Marine Polymer Technologies, Inc. Traitement de maladies avec des nanofibres de poly-n-acetylglucosamine
ES2637286T3 (es) * 2011-07-08 2017-10-11 Defensin Therapeutics Aps Tratamiento oral de la enfermedad inflamatoria intestinal
WO2013026794A1 (fr) 2011-08-19 2013-02-28 Novozymes Nouveau peptide immunomodulateur
US10257564B2 (en) * 2013-01-24 2019-04-09 Saturn Licensing Llc Distributed non-real-time content
CN104628864B (zh) * 2013-11-14 2020-04-10 中国医学科学院医药生物技术研究所 一种抗肿瘤融合蛋白EL-defensin、其编码基因和用途
JP2019514908A (ja) * 2016-04-29 2019-06-06 ディフェンシン セラピューティクス エーピーエス 肝臓、胆管および膵臓の障害の治療
JP2020512287A (ja) 2016-12-13 2020-04-23 ディフェンシン セラピューティクス エーピーエス 肺の炎症性疾患を処置するための方法
EP3706773A2 (fr) 2017-11-10 2020-09-16 Defensin Therapeutics ApS Maturation de la défense des muqueuses et de la fonction intestinale/pulmonaire chez le nourrisson prématuré
RU2020116903A (ru) 2017-11-24 2021-12-24 Дефенсин Терапьютикс Апс Профилактика и лечение реакции "трансплантат против хозяина" с помощью дефензинов
KR102244161B1 (ko) * 2018-08-31 2021-04-26 주식회사 나이벡 다중의 질환 바이오마커의 기능 및 발현을 억제하는 펩타이드의 신규한 용도
CN113684162B (zh) * 2021-06-03 2024-02-27 江南大学 一种表达小鼠防御素mBD14基因的重组植物乳杆菌及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
DE4343591A1 (de) 1993-12-21 1995-06-22 Evotec Biosystems Gmbh Verfahren zum evolutiven Design und Synthese funktionaler Polymere auf der Basis von Formenelementen und Formencodes
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6576755B1 (en) * 1997-09-10 2003-06-10 Zymogenetics, Inc. Beta-defensins
DE19957043A1 (de) * 1999-11-26 2001-06-07 Forssmann Wolf Georg Neue Defensine
US7338936B2 (en) * 2000-11-28 2008-03-04 House Ear Institute Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis
US20080194481A1 (en) * 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
FR2841556B1 (fr) 2002-07-01 2007-07-20 Centre Nat Rech Scient Peptides ayant des proprietes antimicrobiennes et les compositions les contenant notamment pour la conservation des aliments
JP2006514106A (ja) * 2002-12-19 2006-04-27 ヒルマン，イチャク 抗菌ペプチド阻害剤による疾患治療
US20070207209A1 (en) 2004-08-27 2007-09-06 Murphy Christopher J Trophic factor combinations for nervous system treatment
GB0514482D0 (en) * 2005-07-14 2005-08-17 Ares Trading Sa Protein
WO2007081486A2 (fr) 2005-12-15 2007-07-19 Ventria Bioscience Administration orale de defensines pour traiter des maladies intestinales
WO2007087557A2 (fr) 2006-01-24 2007-08-02 University Of Maryland Biotechnology Institute Microspheres enrobées d'une proteine de couche superficielle et leurs utilisations
CA2699163A1 (fr) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Utilisation d'un peptide en tant qu'agent therapeutique
EP2320929B1 (fr) 2008-07-18 2019-05-29 Defensin Therapeutics ApS Bêta-défensines humaines pour son utilisation dans le traitement des maladies inflammatoires
BRPI0915973A2 (pt) 2008-07-18 2013-05-07 Novozymes Adenium Biotech As uso de uma beta defensina humana
EP2320928B1 (fr) 2008-07-18 2012-11-07 Novozymes Adenium Biotech A/S Traitement de la polyarthrite rhumatoïde avec des bêta défensines humaines
ES2637286T3 (es) 2011-07-08 2017-10-11 Defensin Therapeutics Aps Tratamiento oral de la enfermedad inflamatoria intestinal
WO2013026794A1 (fr) 2011-08-19 2013-02-28 Novozymes Nouveau peptide immunomodulateur

Also Published As

Publication number Publication date
US8802621B2 (en) 2014-08-12
US20140135258A1 (en) 2014-05-15
WO2010007166A2 (fr) 2010-01-21
EP2320930A2 (fr) 2011-05-18
US8232242B2 (en) 2012-07-31
CN102159233A (zh) 2011-08-17
EA201170219A1 (ru) 2011-08-30
IL213680A0 (en) 2011-07-31
US20110251139A1 (en) 2011-10-13
BRPI0924481A2 (pt) 2015-08-11
IL210715A0 (en) 2011-03-31
JP2011528333A (ja) 2011-11-17
ZA201100461B (en) 2014-03-26
AR081948A2 (es) 2012-10-31
US20100016230A1 (en) 2010-01-21
TW201004640A (en) 2010-02-01
PH12012501542A1 (en) 2015-11-09
CA2750727A1 (fr) 2010-01-21
NZ590468A (en) 2012-06-29
EP2399600A1 (fr) 2011-12-28
AP2011005538A0 (en) 2011-02-28
US9279010B2 (en) 2016-03-08
MX2011000568A (es) 2011-02-23
KR20110092325A (ko) 2011-08-17
AU2009272681A1 (en) 2010-01-21
AR072032A1 (es) 2010-07-28
WO2010007166A3 (fr) 2010-06-03
CL2011000099A1 (es) 2011-10-07
CN102247591A (zh) 2011-11-23
SG172709A1 (en) 2011-07-28
US20120309678A1 (en) 2012-12-06
NZ593653A (en) 2012-09-28
JP2011225596A (ja) 2011-11-10
TW201138810A (en) 2011-11-16
AP2011005755A0 (en) 2011-06-30
CA2730789A1 (fr) 2010-01-21
EA201100910A1 (ru) 2012-05-30

Similar Documents

Publication Publication Date Title
BRPI0915973A2 (pt) uso de uma beta defensina humana
EP2320929B1 (fr) Bêta-défensines humaines pour son utilisation dans le traitement des maladies inflammatoires
US9833495B2 (en) Oral treatment of inflammatory bowel disease
US20120309686A1 (en) Treatment of Rheumatoid Arthritis With Mammal Beta Defensins
AU2011203033A1 (en) Treatment of inflammatory bowel diseases with mammal beta defensins
Class et al. Patent application title: Treatment Of Rheumatoid Arthritis With Mammal Beta Defensins Inventors: Tanja Maria Rosenkilde Kjaer (Holte, DK) Tanja Maria Rosenkilde Kjaer (Holte, DK) Thomas Kruse (Copenhagen N, DK) Per Holse Mygind (Vaerloese, DK) Per Holse Mygind (Vaerloese, DK) Karoline Sidelmann Brinch (Copenhagen Nv, DK) Karoline Sidelmann Brinch (Copenhagen Nv, DK) Soeren Kjaerulff (Holte, DK) Birgitte Andersen (Bagsvaerd, DK) Birgitte Andersen (Bagsvaerd, DK) Assignees: Novozymes A/S

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.